Brigatinib Effective in ALK+ NSCLC
Copyright policy )Brigatinib Effective in ALK+ NSCLC
Abstract Results from a phase I/II trial indicate that the investigational ALK inhibitor brigatinib is active in patients with ALK-rearranged non–small cell lung cancer. Patients who had previously received crizotinib—as well as those who hadn't—responded to the drug, which was also active in patients with brain metastases.
Lung Neoplasms, Clinical Trials, Phase I as Topic, Brain Neoplasms, Receptor Protein-Tyrosine Kinases, Survival Analysis, Disease-Free Survival, Drug Administration Schedule, Clinical Trials, Phase II as Topic, Organophosphorus Compounds, Pyrimidines, Treatment Outcome, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Sample Size, Mutation, Humans, Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors
Lung Neoplasms, Clinical Trials, Phase I as Topic, Brain Neoplasms, Receptor Protein-Tyrosine Kinases, Survival Analysis, Disease-Free Survival, Drug Administration Schedule, Clinical Trials, Phase II as Topic, Organophosphorus Compounds, Pyrimidines, Treatment Outcome, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Sample Size, Mutation, Humans, Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!